Gilead Sciences Ranks 86th in Trading Volume with $808 Million as HIV Franchise Drives Bullish Outlook

On March 26, 2025, Gilead Sciences (GILD) saw a trading volume of $808 million, ranking 86th in the day's stock market activity. The stock rose by 1.28%, marking its second consecutive day of gains, with a total increase of 2.37% over the past two days.

Citigroup has expressed a strong bullish stance on Gilead's HIV franchise, highlighting it as the company's most significant value driver. The firm anticipates that a robust launch of lenacapavir in pre-exposure prophylaxis (PrEP) and the expansion of several differentiated HIV treatment combinations will more than offset potential challenges, such as the inclusion of Biktarvy in the 2028 Inflation Reduction Act negotiations and minor adjustments to HIV prevention policies.

Gilead recently announced positive data on lenacapavir, a twice-yearly injection aimed at preventing HIV, with plans to roll it out this summer. The drug is projected to reach peak annual sales of $6 billion by 2030. Despite concerns over potential cuts in federal funding for domestic HIV prevention, Citigroup remains optimistic, noting that such cuts would primarily affect statewide prevention initiatives rather than reimbursement for treatments like lenacapavir.

Additionally, Gilead has acknowledged that changes to Medicare's prescription drug plan, including a $2,000 spending cap, will result in $1.1 billion in lost revenues for the company this year. However, Citigroup maintains its bullish outlook on Gilead's HIV franchise, citing a meaningful new product cycle for long-acting oral medications and modeling Biktarvy's 2030 peak sales at $15 billion. The firm has kept a Buy rating on Gilead with a $125 price target.